Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 7/20 | 0.39 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.35 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 4/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.33 |
| ▸ | MMP13 | P45452 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | TRPV3 | Q8NET8 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29907501 | 0.80 | KDM4A (0.41) | KDM4ETRPV3 | |
| SCHEMBL22551972 | 0.80 | KDM4A (0.41) | KDM4ETRPV3 | |
| SCHEMBL22551971 | 0.78 | ADORA2A (0.43) | ADORA2AADORA1TRPV3 | |
| SCHEMBL26456159 | 0.76 | NCF1 (0.41) | P2RX7KCNH2SCN5A | |
| SCHEMBL22551875 | 0.73 | NCF1 (0.38) | KCNH2SCN5A | |
| SCHEMBL29907664 | 0.73 | NCF1 (0.38) | KCNH2SCN5A | |
| SCHEMBL26126280 | 0.71 | HCAR3 (0.44) | HCAR3KDM4EMEN1KMT2A | |
| SCHEMBL15076836 | 0.68 | NCF1 (0.43) | KCNH2SCN5A | |
| SCHEMBL29658998 | 0.68 | NCF1 (0.43) | KCNH2SCN5A | |
| SCHEMBL21730237 | 0.68 | KDM4A (0.43) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230135068-A1 | PYRAZINE COMPOUNDS AND USES THEREOF | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2023-05-04 | — | — | US | disclosed |
| US-11571420-B2 | Pyrazine compounds and uses thereof | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2023-02-07 | — | — | US | disclosed |
| US-20210251989-A1 | PYRAZINE COMPOUNDS AND USES THEREOF | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2021-08-19 | — | — | US | disclosed |
| US-10898481-B2 | Pyrazine compounds and uses thereof | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2021-01-26 | — | — | US | disclosed |
| US-20200330458-A1 | PYRAZINE COMPOUNDS AND USES THEREOF | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2020-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10898481-B2 | Pyrazine compounds and uses thereof | ADORA2A, ADORA2B, ADORA1 | ADORA2A 1/4885HCAR3 177/4885ADORA1 3/4885 |
| US-20230135068-A1 | PYRAZINE COMPOUNDS AND USES THEREOF | ADORA2A, ADORA2B, ADORA1 | ADORA2A 1/4885HCAR3 177/4885ADORA1 3/4885 |
| US-11571420-B2 | Pyrazine compounds and uses thereof | ADORA2A, ADORA2B, ADORA1 | ADORA2A 1/4885HCAR3 177/4885ADORA1 3/4885 |
| US-20200330458-A1 | PYRAZINE COMPOUNDS AND USES THEREOF | ADORA2A, ADORA2B, ADORA1 | ADORA2A 1/4885HCAR3 177/4885ADORA1 3/4885 |
| US-20210251989-A1 | PYRAZINE COMPOUNDS AND USES THEREOF | ADORA2A, ADORA2B, ADORA1 | ADORA2A 1/4885HCAR3 177/4885ADORA1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.